Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00758524 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 628
- Enrollment target
NCT00758524: Completed Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT00758524 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 628 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (372% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00758524, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 628 participants
- Enrollment target
Study Summary
This study was a proof-of-efficacy, dose finding study of LCI699 in participants with mild-to-moderate uncomplicated essential hypertension in order to assess the blood pressure (BP) lowering effect, safety and tolerability of LCI699 as compared to placebo and eplerenone.
Primary Outcome
Automated arterial BP determinations were made after the participant was in the sitting position for 5 minutes according to the Guidelines for management of hypertension: report of the 4th working party of the British Hypertension Society, 2004-BHS IV, using an automated BP device (such as the Omron BP monitor). The change in the MSDBP was calculated comparing the Week 8 readings to the readings taken at Baseline. The change from baseline in MSDBP was analyzed using an analysis of covariance mod
Interventions
- DRUG LCI699
- DRUG Eplerenone
- DRUG LCI699-matching Placebo
- DRUG Eplerenone-matching Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 628 participants |
| Start Date | 2008-09-11 |
| Est. Completion | 2009-07-02 |
| Phase | Phase 2 |
What the finished NCT00758524 record still lists
NCT00758524 is an interventional study that assigns participants to a tested intervention. The registered 628 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (372% higher).
The record links to 0 conditions, and to 4 interventions - of which LCI699 is the first listed.
NCT00758524 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00758524 about?
NCT00758524 is a clinical study titled "A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension". This study was a proof-of-efficacy, dose finding study of LCI699 in participants with mild-to-moderate uncomplicated essential hypertension in order to assess the blood pressure (BP) lowering effect, safety and tolerability of LCI699 as compared to placebo and eplerenone.
What is the current status of trial NCT00758524?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 628 participants. The study started on 2008-09-11. Estimated completion is 2009-07-02.
What interventions are being tested in trial NCT00758524?
The interventions under investigation include: LCI699 (DRUG), Eplerenone (DRUG), LCI699-matching Placebo (DRUG), Eplerenone-matching Placebo (DRUG).
Who is sponsoring clinical trial NCT00758524?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00758524's enrollment target sits among peer trials
628 52nd of 2000 higher than 1,949 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04704921 · 630 participants · Phase 2
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
- NCT04707729 · 630 participants · NA
ROX Index for the Timing of Intubation in Nasal High Flow
- NCT05061550 · 630 participants · Phase 2
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- NCT05224440 · 630 participants · NA
National Sponsorship Program for Transitioning Service Members
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI